MS
PHAT icon

Maven Securities’s Phathom Pharmaceuticals PHAT Stock Holding History

Maven Securities’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-14,753
Closed -$497K – 1264
2020
Q4 		$497K Buy
+14,753
New +$598K 0.05% 359

Other funds holding PHAT

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Maven Securities's PHAT Position: Q1 2021 in Review

Maven Securities sold out of Phathom Pharmaceuticals (PHAT) in Q1 2021, closing a stake of 14,753 shares — an estimated $497K sold.

Maven Securities first reported a position in PHAT in Q4 2020 and held it in 1 quarter. The position peaked at $497K in Q4 2020. 84 funds tracked by Wall St. Rank hold PHAT as of Q1 2021.

  • Maven Securities reported no remaining Phathom Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Maven Securities sold 14,753 Phathom Pharmaceuticals shares in Q1 2021, an estimated $497K.
  • Maven Securities first reported a position in Phathom Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Maven Securities's Phathom Pharmaceuticals position peaked at $497K in Q4 2020.
  • 84 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2021.

Based on Maven Securities's 13F filing for Q1 2021, filed 17 May 2021.